spondyloarthropathies, they are separate entities. Both are distinct from rheumatoid arthritis.

Darren R. Blumberg and Victor S. Sloan
Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

References

Reply to Drs. Blumberg and Sloan

To the Editor: I concur with your comments. After reviewing the literature related to foodborne disease, it appears that the original classification of reactive arthritides has been in error for some time. I certainly appreciate the correction.

James A. Lindsay
University of Florida, Gainesville, Florida, USA

Cost of Blood Screening

To the Editor: In reference to G.A. Schmunis’ article on the risk for transfusion-transmitted infections in Central and South America (1), I would like to comment on the cost of blood screening. In a screening program, the objective is to have safe blood units, not to assess the prevalence of different infections among potential or actual donors. Thus, while acknowledging all infections present in a given donor or potential donor is not required, detecting at least one of the infections that would make a donor noneligible is. If samples from every potential donor are subjected (by default) to all the tests, information on every infection present is provided, and the cost of screening this donor is the sum of the cost of every test applied; in this case, both the information and the cost are greater than necessary.

Information on the prevalence of bloodborne infections among the general population or, preferably, among potential donors (particularly where professional donors are frequent) along with information on the costs of the tests to be used can form the basis of a stepwise screening scheme. Tests for infections with the highest prevalence would be applied first. For example, in many areas of Peru, using the Venereal Disease Research Laboratory (VDRL) test (for screening Treponema pallidum infection) first would reduce the number of samples to be subjected to other more expensive and often less available tests (e.g., HIV enzyme-linked immunosorbent assay [ELISA] or hepatitis C virus [HCV] ELISA); in others areas, a test for hepatitis B virus antigen (HBAg) should be used before HIV ELISA. The reduction in cost provided by stepwise screening will depend on the prevalences of the more frequent infections and the frequency of concurrent infections.

The questionnaires applied to candidate donors should be validated, and the benefit of using them should be assessed. In most settings, candidate donors are either ignorant of their status as carriers of bloodborne infection or ready to deny it; therefore, the questionnaire is of little use. In some cases candidate donors are turned down because of “hepatitis history” when in fact they have not had bloodborne hepatitis.

Finally, screening tests seem to be quite more expensive than reported in Table 4 of the Schmunis article. In Lima, at a ministry of health facility, some prices are as follows: HIV ELISA US$12.50, VDRL US$6.40, HBAg US$13.90.

O. Jaime Chang
Instituto Nacional de Salud, Ministerio de Salud, Lima, Peru

Reference